PFE - IPO Update: Revolution Medicines Proposes IPO Terms
Quick Take
Revolution Medicines (RVMD) intends to raise $150 million from the sale of its common stock, according to an amended registration statement.
The company is in Phase 1/2 trials for the development of treatments for various types of cancers.
RVMD has produced promising early results for its lead candidate, has strong collaboration relationships and a large and growing market, so RVMD may be worth considering for long-term hold life science investors.
Company & Technology
Redwood City, California-based Revolution was founded to advance a pipeline of drug candidates for the treatment of a